The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

about

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

Item

http://www.wikidata.org/entity/Q47427370

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@en

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@nl

type

Item

label

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@en

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@nl

prefLabel

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@en

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@nl

P1476

The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.

@en

P2093

Hansita B Patel

http://www.w3.org/2001/XMLSchema#string

Jason M Cota

http://www.w3.org/2001/XMLSchema#string

Kathleen A Lusk

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

Extended-spectrum β-lactamases in Gram Negative Bacteria.

Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

P304

897190017743134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0897190017743134

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29166830

http://www.w3.org/2001/XMLSchema#string